Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Study: Different RAS mutations each have unique impact on AML, drug response Approximately 10% to 20% of patients with acute myeloid leukemia (AML) have a mutation in the RAS genetic pathway at ...

With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations ... a mechanism by which acute myeloid leukemia (AML ...

TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML ...

Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting. The additional data presented include data for 21 patients with a FLT3 mutation (FLT3m) who had received fewer than 3 lines of prior ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

The Company’s lead clinical-stage compound tuspetinib (TUS) is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or ...

of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response ...